A case report of primary non-hodgkin lymphoma of the bile duct Authors: Miao-xia Chen, Yong-jian Li, Lei Leng, Xiao-pei Chen, Chuang-jia Zhang, Si-bi Yang, Shu-ya Feng, Wen-feng Deng, Fan Xu Published: 2026 ABSTRACT AbstractPrimary biliary non-Hodgkin’s lymphoma (PBNHL) is an extremely rare biliary malignancy often misdiagnosed as cholangiocarcinoma due to nonspecific imaging. Delayed recognition can result in unnecessary surgery and treatment delays, as chemotherapy is the primary therapy. We report an elderly male presenting with upper abdominal pain, initially suspected of cholangiocarcinoma, but diagnosed with B-cell non-Hodgkin’s lymphoma (B-NHL) on histopathology. Due to poor baseline performance and multiple acute complications, he received only two days of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and subsequently died from sepsis. We report a case of PBNHL, emphasizing its characteristic cholangiographic features and the potential contribution of immunosuppressive conditions, including Epstein–Barr virus (EBV) infection.Keywords: Non-Hodgkin’s lymphoma, Malignant lymphoma, Bile duct lymphoma, Case report Introduction Lymphoma is a systemic lymphoproliferative malignancy classified as Hodgkin or non-Hodgkin lymphoma (NHL). Biliary involvement usually arises from metastasis and is considered a subtype of NHL [1]. Primary biliary non-Hodgkin lymphoma (PBNHL) is extremely rare and often presents with obstructive jaundice. Its nonspecific clinical and imaging features, which can mimic cholangiocarcinoma, make preoperative diagnosis challenging, frequently leading to unnecessary surgery [2, 3].In this case report, we present an elderly patient with a history of nasopharyngeal carcinoma and chronic hepatitis B, in whom persistent Epstein–Barr virus (EBV) infection may have contributed to the development of B-cell lymphoma. Diagnosis was confirmed by CT-guided liver biopsy, highlighting the importance of considering PBNHL in patients with atypical biliary strictures. Case presentation A 71-year-old man was admitted to the hospital with a one-day history of persistent, dull pain in the right upper quadrant. The pain was non-radiating and unrelated to meals or changes in position. He reported no fever, chills, nausea, vomiting, or pale stools. His medical history was notable for nasopharyngeal carcinoma, previously treated with radiotherapy and chemotherapy, with recent imaging showing no evidence of disease progression; hypertension, managed with irbesartan but with suboptimal control; coronary artery disease, treated with aspirin and atorvastatin; and chronic hepatitis B infection. He denied smoking, alcohol consumption, or a family history of relevant diseases. On physical examination, the patient’s vital signs were within normal limits. Scleral and cutaneous jaundice was observed, without palmar erythema or spider angiomas. The abdomen was soft and non-distended, with localized tenderness in the right upper quadrant; Murphy’s sign was negative. No hepatosplenomegaly, palpable masses, or shifting dullness was noted. Superficial lymphadenopathy was absent. Laboratory investigations (Table 1) revealed elevated levels of interleukin-6 (IL-6), procalcitonin, and D-dimer, as well as abnormal liver function tests, increased serum lipase suggestive of pancreatitis, and elevated cancer antigen 125 (CA 125). Notably, lactate dehydrogenase (LDH) levels were within the normal range. Table 1Laboratory findingsValueReference rangeComplete blood count Erythrocytes (RBCs), × 1012/L3.373.5–5.5 Leukocytes (WBCs), × 10⁹/L7.734.0–10.0 Hemoglobin (Hb), g/L102.0120.0–160.0 Platelets, × 10⁹/L201.0100.0–300.0 Lymphocyte, × 10⁹/L0.760.8–4.0 Lymphocytes, %0.0980.2–0.4Two infection markers Interleukin-6 (IL-6), pg/mL63.460.0–7.0 Procalcitonin (PCT), ng/mL0.120.0–0.1Liver function Lactate dehydrogenase (LDH), U/L163.780.0–240.0 Aspartate aminotransferase (AST), U/L106.50.0–45.0 Alanine aminotransferase (ALT), U/L135.50.0–45.0 Gamma-glutamyl transferase (GGT), U/L288.00.0–45.0 Total bilirubin (TBIL), umol/L99.15.1–23.9 Direct bilirubin (DBIL), umol/L57.21.7–6.8 Indirect bilirubin (IBIL), umol/L41.93.0–19.0 Total bile acid (TBA), umol/L378.40.0–9.0Pancreatitis Amylase, U/L197.028.0–100.0 Lipase, U/L235.15.6–51.3 D-Dimers, ug/L8820.00.0–550.0 Fibrinogen, g/L4.91.8–4.0Tumor markers Alpha-fetoprotein (AFP), IU/mL0.890.0–5.8 Carcinoembryonic antigen (CEA), ug/L4.510.0–4.3 Cancer antigen 125(CA125), U/mL45.30.0–35.0 Cancer antigen 199(CA199), U/mL29.80.0–35.0 Laboratory findings Contrast-enhanced computed tomography (CT) of the chest, abdomen, and pelvis demonstrated a large, intermediate-density mass at the hepatic hilum, involving the common hepatic artery and main portal vein (Fig. 1a). The mass exhibited heterogeneous delayed enhancement on contrast imaging (Fig. 1b) and was noted to encase and invade the common hepatic artery, main portal vein, and their branches (Fig. 1c), leading to vascular narrowing and a filling defect with occlusion of the main portal vein (Fig. 1d). Stenosis of the biliary structures at the hepatic hilum was also observed. No definite recurrence was detected in the nasopharynx or periportal lymph nodes on the current examination. The initial diagnosis was hilar cholangiocarcinoma with lymph node metastasis. a–e CT scan images. a Intermediate-density mass at the hepatic hilum with ill-defined margins (Box). b–d Heterogeneous delayed enhancement of the mass in arterial, portal, and delayed phases; encasement of the common hepatic artery and filling defect in the main portal vein (red box and arrow). e A CT-guided liver mass biopsy. f PTCD showing dilated right intrahepatic bile ducts (white arrow) with smooth margins and obstruction of common hepatic duct outflow To clarify the pathology of the hilar hepatic mass, a CT-guided liver biopsy (Fig. 1e) was performed on the third day after admission. Bone marrow aspiration and biopsy showed no evidence of marrow infiltration. Histopathological examination (Fig. 2a–i) revealed sheets of atypical cells infiltrating the perihepatic area. The cells displayed slightly enlarged, hyperchromatic nuclei with scant cytoplasm, rare mitotic figures, and a starry-sky pattern. Immunohistochemistry demonstrated positivity for P53 (~ 80%), Ki-67 (~ 95%), LCA (+++), CD21 (+), CD20 (+), CD10 (+), BCL-6 (+), and CD79a (+), with negative staining for CD3. Molecular studies revealed positive Epstein-Barr virus-encoded RNA (EBER) staining (++), confirming the final diagnosis of B-NHL. a–i Histopathological findings. Histopathological findings (all × 100 magnification): a H&E staining showing atypical cells with a starry-sky pattern; b–i Immunohistochemical staining for LCA, P53, BCL6, CD3, CD10, CD79a, EBERs, and Ki67 Percutaneous transhepatic cholangial drainage (PTCD) was performed on the 9th day after admission to relieve biliary obstruction. Intraoperative cholangiography revealed marked dilation of the right intrahepatic bile ducts with smooth margins and obstruction of the common hepatic duct outflow. The left intrahepatic bile ducts and common bile duct were not visualized (Fig. 1f). On day 14 post-admission, the patient (with a history of prolonged bed rest) developed acute dyspnea and tachycardia, and acute pulmonary embolism was confirmed by contrast-enhanced CTPA (computed tomography pulmonary angiography). Concurrently, he had pulmonary infection with persistently elevated inflammatory markers, which stabilized after anticoagulant and anti-infective therapy. He was transferred to a specialized ward on day 48 post-admission and received 2 days of R-CHOP. However, he had high-risk molecular abnormalities (MYC rearrangement, TP53 mutation) and was classified as ultra-high-risk by IPI, R-IPI and NCCN-IPI criteria. Severe acute complications (pulmonary embolism, septic shock, gastrointestinal bleeding) and poor baseline performance status precluded chemotherapy. The patient died of sepsis approximately 3 months after diagnosis, with extremely poor prognosis (The clinical timeline of the patient is presented in Table 2). Table 2Timeline of clinical eventsDayEventDay 1Admission: 71-year-old man presents with persistent dull right upper quadrant pain. No fever, chills, nausea, vomiting, or pale stoolsDay 1Initial evaluation: vital signs normal; abdominal tenderness in right upper quadrant; jaundice noted; labs show abnormal liver function, elevated IL-6, procalcitonin, D-dimer, lipase, CA-125; LDH normalDay 1–2Imaging: contrast-enhanced CT shows large hilar mass involving common hepatic artery and main portal vein, heterogeneous enhancement, biliary stenosis; initial suspicion of cholangiocarcinomaDay 3CT-guided liver mass biopsy performed. Bone marrow biopsy shows no infiltration. Histopathology confirms B-cell NHL; EBER positiveDay 9Percutaneous transhepatic cholangial drainage (PTCD) performed for biliary obstruction. Cholangiography shows smooth right intrahepatic bile duct dilation and obstruction of common hepatic duct outflowDay 14Acute dyspnea and tachycardia; contrast-enhanced CTPA confirms pulmonary embolism. Concurrent pulmonary infection noted; inflammatory markers elevatedDay 14–48Anticoagulant and anti-infective therapy administered; patient stabilizedDay 48Transferred to specialized ward; received 2 days of R-CHOP chemotherapy ~ Day 90Patient dies of sepsis due to severe complications (pulmonary embolism, infection, poor baseline status) Timeline of clinical events Discussion PBNHL is exceptionally rare, with the first case reported by Nguyen in 1982[4]. A systematic literature search was conducted in PubMed, Wanfang Data, and the Chinese Medical Journal Full-text Database, with additional searches in Google Scholar and manual screening of references. In PubMed, the search strategy combined the MeSH terms “Lymphoma,” “Bile Ducts,” and “Primary.” Corresponding Chinese keywords were applied in the Wanfang and CMJ databases to ensure comprehensive coverage. This strategy identified 61 eligible case reports of primary biliary malignant lymphoma, with diffuse large B-cell lymphoma (DLBCL) being the most frequently reported subtype. To ensure the depth and reliability of analyses on biliary tract imaging features and their association with EBV/HIV status, we further applied strict inclusion criteria: cases must have evaluable biliary tract imaging or documented EBV and/or HIV test results. Accordingly, 13 cases were excluded due to incomplete data (e.g., no cholangiography or unreported virological testing).Finally, 48 high-quality casesconstituted the core cohort for subsequent analyses of imaging patterns and virus-related associations. The demographic and key clinical information of these 48 cases are summarized in Table 3, while key information relevant to the study objectives is further presented in Table 4. Table 3Data of 49 casesAuthorSex/Age(y)HBV/HCV(+)/(-)EBV/HIV(+)/(-)Angiographic Results Preliminary diagnosisHistopathologic diagnosisTreatment modalitysurvival time(month)1Kang et al. [1]Female/73(−)Pancreatic cancer and CholangiocarcinomaMALT-type low-grade B-cell lymphomaSurgery>232Nguyen [4]Male/59(−)PTCD/ERCP: distal hepatic duct smooth stenosisSclerosing cholangitisDiffuse lymphoma of lymphoid tissue cellsSurgeryChemotherapy83Takehara et al. [5]Male/60PTCD revealed smooth stenosis of the CBDCholangitisExtranodal bile duct non-Hodgkin lymphoma, diffuse medium-sized cell typeSurgery chemotherapyUnknown4Kaplan et al. [6]Male/42HIV(+)ERCP revealed two separate smooth stenoses in the mid-CBDCholangitisHigh-grade non-Hodgkin lymphomaSurgery chemotherapy105Tartar and Balfe [7]Male/48PTCD revealed smooth, tapered common hepatic duct stenosisCholangiocarcinomaNon-Hodgkin lymphoma of the bile duct wallSurgery chemotherapy>146Yoon et al. [8]Male/62(−)ERCP: smooth stenosis in multiple bile duct segmentsKlatskin tumorMALT lymphomaSurgeryUnknown7Sugawara et al. [9]Male/33PTBD revealed very smooth hilar stenosis with an extramural massKlatskin tumorFollicular lymphomaSurgery>128Joo et al. [10]Female/21(-)ERCP: long-segment CBD stenosis, upstream dilationCholangiocarcinomaDLBCLSurgeryChemotherapy Radiotherapy>179Dote et al. [11]Male/63(−)HIV(−)MRCP revealed a tapered distal CBD stenosis with upstream bile duct dilationPancreatic head cancer or cholangiocarcinoma.DLBCLSurgeryChemotherapy>810Brouland et al. [12]Female/34Intraoperative cholangiography revealed proximal CBD stenosis, distal duct normalCholangiocarcinoma and sclerosing cholangitisT-cell rich B-cell lymphomaSurgeryChemotherapy>4811Chiu et al. [13]Female/25ERCP revealed a tapered stenosis in the midportion of the CBDT-cell derived lymphomaSurgery112Maymind et al. [14]Female/39ERCP: CBD mid stenosis, upstream dilationDLBCLSurgeryChemotherapy Radiotherapy>1313Iijima et al. [15]Female/70Multiple imaging: biliary stenosis with typical featuresCholangiocarcinomaGerminal center B-cell-like DLBCLChemotherapy>1914Zakaria et al. [16]Male/57(−)ERCP showed mid-CBD stenosis; MRCP showed distal CBD tapered stenosisCholangiocarcinomaDLBCLSurgeryChemotherapy>6015Podbielsk et al. [17]Male/66(−)HIV(+)ERCP: distal common hepatic duct stenosis, left hepatic duct not visualizedKlatskin tumor and Sclerosing cholangitisDLBCLSurgeryUnknown16Denise et al. [18]Male/32HIV(−)ERCP revealed a smooth, progressively narrowing long-segment biliary stenosisDLBCLSurgeryChemotherapyIn remission17Oda et al. [19]Male/58ERCP and ENBC indicate mid-to-upper CBD obstructionCholangiocarcinomaLymphoma, diffuse, mixed small and large cell type.Surgery118Corbinais et al. [20]Male/29EBV(−), HIV(−)MRCP: intrahepatic bile duct dilation, proximal CBD "carpal tail" appearanceCholangiocarcinomaAlpha-beta (αβ) type polymorphic T-cell lymphoma, predominantly of medium to large cell size.SurgeryChemotherapy>1219Eliason et al. [21]Female/41EBV(−)ERCP failed to visualize the hepatic ductsKlatskin tumorFollicular center cell-type diffuse large B-cell lymphomaSurgeryUnknown20Gravel et al. [22]Male/4(−)EBV(−)Sclerosing cholangitisPre-B cell lymphoblastic lymphomaSurgeryChemotherapy>1821Khozeimeh et al. [23]Male/32(−)EBV(−)ERCP: CBD stenosis with proximal duct dilation.CholangiocarcinomaFollicular lymphomaSurgeryChemotherapy>7222Ferluga et al. [24]Female/63ERCP: cystic duct stenosis, intrahepatic bile duct dilationKlatskin tumorGrade II follicular lymphomaSurgery>3623Suzuki et al. [25]Female/71EBV(−)MRCP/ERCP: lower CBD stenosis, upper segment dilationCholangiocarcinomaMALT lymphomaSurgery>4024Jho et al. [26]Female/48MRCP: porta hepatis mass, bile duct dilation. PTCD: dual stenosisKlatskin tumorDLBCLSurgeryChemotherapy>3625Shito et al. [27]Male/71(−)ERCP/MRCP: common hepatic duct junction stenosis.CholangiocarcinomaMALT lymphomaSurgeryChemotherapy>4526Kang et al. [28]Male/60MRCP: CHD stenosis, bile duct dilation. ENBC: porta hepatis long-segment stenosis.Klatskin tumorDLBCLSurgeryChemotherapyUnknown27Luigiano et al. [29]Male/30ERCP/Cholangiography: distal CBD stenosis, proximal dilationAcute pancreatitisDLBCLSurgeryChemotherapy>628Elbanna et al. [30]Male/71(−)MRCP: mid-CBD severe stenosis, upstream dilationCholangiocarcinomaFollicular subtype non-Hodgkin lymphomaSurgeryUnknown29Cho et al. [31]Male/79ERCP: diffuse CBD stenosis, mild intrahepatic bile duct dilation.CholangiocarcinomaMALT-type low-grade B-cell lymphomaSurgeryUnknown30Park et al. [32]Female/86(−)CholangiocarcinomaMALT lymphomaSurgery>1231Pararas et al. [33]Female/61(−)DLBCLChemotherapy>832Kato et al. [34]Male/77(−)ERCP: mid-CBD stenosis. POCS: smooth mass same siteDLBCLSurgeryChemotherapy633Gao et al. [35]Male/AdultEBV(+)MRCP shows thickening of the gallbladder wallCholecystitis and biliary tract infectionNon-Hodgkin lymphoma, NK/T-cell typeSurgery1/634Nakamura et al. [36]Male/67MRCP/ERCP: distal bile duct stenosis, proximal dilationDLBCLChemotherapyUnknown35Durham et al. [37]Male/61HIV(+)ERCP shows bile duct stenosisKlatskin tumorDLBCLSurgeryChemotherapyUnknown36Ito et al. [38]Male/50EBV(+)ERCP didn't show malignant tumorExtranodal NK/T-cell lymphomaChemotherapy1/537Das et al. [39]Male/36(−)HIV(−)ERCP: irregular common hepatic duct stenosis above cystic ductCholangiocarcinomaDLBCLSurgeryChemotherapy>6838Ikuta et al. [40]Male/66MRCP/ERCP: mid-lower bile duct irregular stenosis, mild intrahepatic dilationMALT lymphomaChemotherapyUnknown39Sonal and Kaseb [41]Male/77(−)EBV(−), HIV(-)ERCP shows stenosis of the common hepatic ductCholangiocarcinomaDLBCLSurgeryChemotherapy1240Hwang et al. [42]Male/68ERCP: severe proximal CBD stenosis, upstream dilationKlatskin tumorMALT lymphomaRadiotherapyUnknown41Boccardo et al. [43]Female/76MRCP shows obstructive dilation of the biliary systemMALT lymphomaSurgery142Shimura et al. [44]Male/59PTCD shows stenosis of the extrahepatic bile ductKlatskin tumorMALT lymphomaSurgeryUnknown43Wu et al. [2]Female/59EBV(+)CholangiocarcinomaDLBCLSurgery244Wang et al. [45]Male/66(−)EBV(−)ERCP: long CBD stenosis, proximal duct dilationCholangiocarcinomaDLBCLSurgeryUnknown45Liu et al. [46]Male/57(−)MRCP: porta hepatis mass, bile duct dilation.Klatskin tumorMALT variant extranodal marginal zone B-cell lymphomaSurgery>6046Xia et al. [47]Female/24MRCP: mid-upper CBD wall thickening, biliary obstructionCholangiocarcinomaDLBCLSurgeryChemotherapyUnknown47Xu et al. [48]Male/60TTCG: distal CBD patent, upper portion not visualizedCholangiocarcinomaDLBCLSurgeryChemotherapy>848Wang et al. [49]Male/60(−)HIV(−)CholangiocarcinomaDLBCLTACE Chemotherapy>649This caseMale/71(+)EBV(+)PTCD: dilated right intrahepatic duct, smooth margins, outflow obstructionCholangiocarcinomaDLBCL3 Data of 49 cases Table 4Data summarized from Table 2Viral infection/imaging findingPositive (cases)Negative (cases)Sum (cases)EBV/HIV71118HBV/HCV11920Smooth biliary duct103343HBV Hepatitis B Virus, HCV Hepatitis C Virus, EBV Epstein-Barr Virus, HIV Human Immunodeficiency Virus Data summarized from Table 2 HBV Hepatitis B Virus, HCV Hepatitis C Virus, EBV Epstein-Barr Virus, HIV Human Immunodeficiency Virus PBNHL is an extremely rare subtype of extranodal NHL, accounting for merely 0.4% of all extranodal NHL cases [2]. It predominantly affects middle-aged and elderly populations, with its exact pathogenesis remaining unclear; however, accumulating evidence suggests potential associations with immune dysfunction, chronic inflammation, and viral infections such as EBV, HBV, and HIV [33, 50, 51]. This case involves an elderly patient with a history of nasopharyngeal carcinoma treated with chemoradiotherapy, persistent EBV infection, and a 20-year chronic hepatitis B history—conditions that may have contributed to disease development. EBV is a human lymphotropic virus that primarily infects B lymphocytes. It interacts with the complement receptor CR2 via the viral glycoprotein gp350, and with human leukocyte antigen (HLA) class II molecules via glycoprotein gp42 [52, 54], Previous studies have shown that after EBV infects B cells, an efficient transformation mechanism is triggered: once the EBV genome enters the B cell nucleus, it activates a highly efficient cell growth program—almost all B cells carrying the viral genome in the nucleus express EBV antigens (such as EBNA2), activate cells (such as high expression of CD23), and enter the cell cycle. EBNA2-positive cells are closely related to subsequent cell activation and proliferation, serving as important markers for post-infection cell transformation potential. Studies suggest that EBV infection provides B cells with the ability to grow indefinitely in the early stages of infection [53, 55]. Although a direct causal relationship between the patient’s previous NPC history and PBNHL cannot be conclusively proven, both conditions are associated with EBV, suggesting that chronic EBV infection may play a potential bridging role in the progression of this patient's disease, providing a common pathological foundation for the development of both diseases. Furthermore a review of relevant cases (Table 3) indicates that 38.9% of PBNHL patients are EBV/HIV-positive, and these viral-positive cases tend to have poorer prognoses, supporting the role of viral factors in disease development and progression. Clinically and radiologically, PBNHL is frequently misdiagnosed as cholangiocarcinoma due to overlapping features, although critical distinctions exist. Both conditions commonly present with obstructive jaundice, abdominal discomfort, and weight loss. Imaging studies, however, may aid differentiation: while CT or MRI often show diffuse bile duct wall thickening with luminal narrowing or dilation in both diseases, PBNHL is typically associated with smooth, concentric biliary strictures without mucosal irregularities, whereas cholangiocarcinoma usually causes irregular, eccentric narrowing. In a review of 49 PBNHL cases, 23% (10/43 with available cholangiographic records) exhibited smooth bile duct narrowing, supporting prior observations by Yoon et al. [8] that such imaging findings should prompt high suspicion for PBNHL, even when diffuse duct wall thickening is present. In this case, cholangiography demonstrated typical smooth biliary strictures, and definitive diagnosis was achieved via CT-guided biopsy, thereby avoiding unnecessary surgery and delays in treatment—a common pitfall in misdiagnosed cases. Pathological biopsy remains the gold standard for differentiating PBNHL from cholangiocarcinoma, as clinical and imaging findings alone are insufficient. Endoscopic biopsy is preferred due to its minimally invasive nature, though repeat sampling may be necessary to reduce false-negative results. Accurate histological confirmation is essential because the treatment paradigms differ: PBNHL is primarily managed with systemic therapy, whereas cholangiocarcinoma relies on surgical resection for potential cure. Misdiagnosis may result in inappropriate interventions, either unnecessary surgery for PBNHL or delayed chemotherapy for cholangiocarcinoma, highlighting the indispensable role of tissue diagnosis in guiding management. Currently, no standardized treatment protocol exists for PBNHL, but systemic chemotherapy remains the cornerstone. The R-CHOP regimen has demonstrated efficacy in some patients, whereas ultra-high-risk individuals, as defined by IPI, R-IPI, and NCCN-IPI criteria, may benefit from frontline intensification with the DA-EPOCH-R regimen. For refractory or relapsed disease, platinum-based salvage therapy followed by autologous stem-cell transplantation is an option for eligible patients. Additionally, CD19-targeted CAR T-cell therapy has emerged as a promising second-line strategy for patients ineligible for transplantation, achieving durable remissions in clinical trials [56, 57]. In contrast, cholangiocarcinoma’s curative potential depends on surgical resection, underscoring the necessity of accurate diagnosis to guide appropriate therapy. This case has important limitations. The patient received only two days of R-CHOP chemotherapy due to severe comorbidities—including pulmonary embolism and sepsis—and ultimately succumbed to sepsis three months after diagnosis. Consequently, the efficacy of standard chemotherapy and long-term prognosis cannot be assessed. This outcome highlights a critical clinical observation: PBNHL patients with comorbidities or immunocompromise often exhibit poor treatment tolerance, emphasizing the need for individualized management and proactive complication prevention, particularly against infections. Furthermore, the rarity of PBNHL limits generalizability, and larger, multicenter studies are required to clarify the role of viral infections and immune status in disease pathogenesis, refine diagnostic criteria, and optimize treatment strategies. Conclusion This case underscores that PBNHL can closely mimic cholangiocarcinoma and is frequently misdiagnosed. In patients presenting with atypical clinical or imaging findings, or with a history of malignancy or immunosuppression, the presence of smooth bile duct strictures on cholangiography should prompt consideration of lymphoma. However, cholangiography alone is insufficient for definitive diagnosis; additional diagnostic modalities, such as endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), are recommended. Whenever feasible, preoperative biopsy should be performed to establish histological confirmation, avoid unnecessary surgical intervention, and enable timely initiation of appropriate therapy. Author contributions C.L wrote the main manuscript text and prepared Tables 1 and 2; L analyzed the pathological slides and summarized the results. X reviewed and revised the text and C.Z.Y.F.D collected and sorted out the data, and summarized the literature information. All authors reviewed the manuscript. Funding Guangzhou Science and Technology Project of Health, China [grant numbers: 2025A03J3320]. Data availability The data that support the findings of this study are available from Xu Fan, upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Medical Ethics Committee of Guangzhou Red Cross Hospital Affiliated to Jinan University.This study was conducted in strict accordance with the ethical principles of the Helsinki Declaration. Written informed consent was obtained from the patient. All methods were performed in accordance with relevant guidelines and regulations. Consent for publication Written informed consent was obtained from the patient for the publication of this case report and accompanying images. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data that support the findings of this study are available from Xu Fan, upon reasonable request.